DAPK3 and cervical cancer: In conclusion, we demonstrate the ability of our Naïve Bayesian model-based network for identifying the key double targets AMPK and ZIPK, and provide the dual-target activator (BL-AD008) as a potential new apoptosis-modulating drug for cervical cancer therapy (Figure 10).